| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","company":"Septerna, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_8d512af6864e1e85","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:38:03.046831+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt","source_event_id":"evt_74aa5d5e1d0c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"5b7a2fa8a3e6444b","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-13","2026-04-14","2026-04-13 (press release date)","late 2026 or early 2027 (data anticipated; per Exhibit 99.1 text)"],"entities":[{"asset_class":"equity","name":"Septerna, Inc.","relevance":"high","symbol":"SEPN","type":"issuer"},{"asset_class":"biotech_pipeline","name":"SEP-479","relevance":"high","symbol":"","type":"drug_candidate"},{"asset_class":"individual","name":"Jeffrey Finer, M.D., Ph.D.","relevance":"medium","symbol":"","type":"person"}],"event_type":"research","information_gaps":["The provided text truncates Exhibit 99.1 mid-sentence (\u201cwith the latter assessed by changes in endogenous \u2026\u201d), so specific PD measures/endpoints are not fully disclosed in the excerpt.","The signal does not include any prior-known state to explicitly describe what changed versus earlier filings (only that this 8-K was filed).","No financial guidance or financial statement impact is included in the provided excerpt; Item 7.01 is Regulation FD disclosure.","The excerpt does not provide the full clinical trial protocol details beyond SAD/MAD, endpoints, and enrollment expectation."],"key_facts":["The filing is a Current Report on Form 8-K with Item 7.01 Regulation FD Disclosure.","On April 13, 2026, Septerna issued a press release titled \u201cSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism.\u201d","The press release was furnished as Exhibit 99.1 to the 8-K and incorporated by reference.","On April 13, 2026, Septerna updated its corporate presentation for investor/analyst meetings.","The updated corporate presentation was furnished as Exhibit 99.2 to the 8-K and incorporated by reference.","Exhibit 99.1 states that dosing of the first participants in the Phase 1 clinical trial of SEP-479 began.","Exhibit 99.1 describes the Phase 1 trial as a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy adult volunteers to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).","Exhibit 99.1 states the trial is randomized and placebo-controlled and is expected to enroll up to 150 healthy adult participants.","Exhibit 99.1 states dosing is underway in the SAD portion with escalating oral doses.","Exhibit 99.1 states the MAD portion is designed to evaluate once-daily oral dosing over multiple days, with secondary/exploratory endpoints including PK and PD."],"numeric_claims":[{"label":"Expected enrollment (healthy adult participants)","value":"up to 150"},{"label":"Trial design","value":"SAD and MAD"},{"label":"Dosing schedule (MAD)","value":"once-daily oral dosing over multiple days"}],"primary_claim":"On April 13, 2026, Septerna issued a press release announcing the dosing of the first participants in its Phase 1 clinical trial of SEP-479 and furnished it as Exhibit 99.1 to the 8-K.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Septerna, Inc. filed a Form 8-K on April 13, 2026 (reported in the filing dated April 14, 2026) to furnish Regulation FD disclosures related to its Phase 1 clinical trial initiation for SEP-479 and to provide an updated corporate presentation.","topics":["Form 8-K","Regulation FD Disclosure","Phase 1 clinical trial","SEP-479","hypoparathyroidism","PTH1R agonist","investor corporate presentation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Septerna, Inc. \u00b7 Filed 20260413","ticker":"SEPN","tickers":["SEPN"],"title":"SEPN filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1984086/0001193125-26-152045.txt"}... |